On May 17, the federal government told six drug companies that their 340B contract pharmacy policies were illegal, and it asked them to provide updates by June 1 on their plans to comply with the law.
At least three of
…
Month: June 2021
Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing entities to lose more than a combined total of $125 million per month in 340B program savings, federal filings in
…
The U.S. Centers for Medicare & Medicaid Services (CMS) announced on Monday that Massachusetts’ Medicaid director Daniel Tsai has been named Deputy Administrator of CMS and Director of CMS’s Center for Medicaid and CHIP Services (CMCS). A record 80 million
…
Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health Resources and Services Administration (HRSA), the federal agency responsible for the 340B drug pricing program.
This normally might be a
…
A recent U.S. Supreme Court decision is spurring more states to enact laws banning pharmacy benefit managers (PBMs) from reimbursing 340B pharmacies less for prescription drugs than non-340B providers, health care lawyers say in a new paper.
According to the
…
In his latest column for Omnicell, 340B Report Publisher and CEO Ted Slafsky ponders four burning questions as we approach the first anniversary of drug manufacturers stopping or placing restrictions on 340B drug discounts in the contract pharmacy setting.
SPONSORED CONTENT by Dr. LeeAnn Scheer, Caravan Health
Safety net facilities are celebrating the May 17 HRSA letters to six drug manufacturers affirming they must provide drugs to covered entities through their contract pharmacies at the 340B ceiling price. This decision will help these facilities, many of them rural, stretch this federal program
…
U.S. Health and Human Services (HHS) Secretary Xavier Becerra this morning announced his six appointees to the long-awaited 340B administrative dispute resolution (ADR) board.
The move will be welcomed by the 340B provider community, which has pushed for the creation
…
Hospitals, health centers, and clinics are losing a projected $3.2 billion a year in 340B program savings due to six drug manufacturers’ denials of 340B pricing on drugs shipped to contract pharmacies, the federal government said in a court filing
…
Drug manufacturer AstraZeneca and the federal government are miles apart on what a federal judge should do next after ruling last week that the government had no basis for stating in December that the 340B statute unambiguously requires manufacturers to
…